

GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

Company

2022/05/27 20:09:48



Price

64.45

USD

Difference

-0.04% (-0.03)



Contact Details

GILEAD SCIENCES INC. Tel: 1-650-574-3000
 -- Fax: 1-650-522-5853
 333 Lakeside Drive Web: <http://www.gilead.com>
 94404 Foster City E-mail: -

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	14,772,000,000		15,996,000,000		30,296,000,000	
Common stock capital		1,000,000		1,000,000		1,000,000
Fixed assets	53,180,000,000		52,411,000,000		31,331,000,000	
Equity capital of a company		21,064,000,000		18,221,000,000		22,650,000,000
Cash and cash equivalents	5,338,000,000		5,997,000,000		11,631,000,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		11,610,000,000		11,397,000,000		9,759,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		35,278,000,000		38,789,000,000		29,218,000,000
Different income		-		-		-
Other liabilities		5,254,000,000		9,536,000,000		6,498,000,000
Total assets	67,952,000,000	67,952,000,000	68,407,000,000	68,407,000,000	61,627,000,000	61,627,000,000

Balance notes

	2021	2020	2019
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	14,400	13,600	11,800
Equity ratio	30.99%	26.66%	36.96%
Debt-equity ratio	222.67%	275.04%	170.59%

Others

	2021	2020	2019
Tax Expense Rate	25.09%	94.67%	-3.95%

GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

Income statement

	2021	2020	2019
Turnover	27,372,000,000	24,642,000,000	22,322,000,000
Net income	6,225,000,000	123,000,000	5,386,000,000
EBIT	8,645,244,300	2,471,800,100	5,734,613,500
Operating income before taxes	8,278,000,000	1,669,000,000	5,160,000,000
Cash Flow	11,384,000,000	8,168,000,000	9,144,000,000
Net interest income	-1,001,000,000	-984,000,000	-995,000,000
Research and development expenses	5,363,000,000	4,857,000,000	8,306,000,000
Income taxes	2,077,000,000	1,580,000,000	-204,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,771,006	1,688,158	1,762,492

Board of Directors

Members of Management Board

Jacqueline Barton	Member of Board of Directors
Jeffrey Bluestone	Member of Board of Directors
Sandra Horning	Member of Board of Directors
Anthony Welters	Member of Board of Directors
Harish M. Manwani	Member of Board of Directors
Javier Rodriguez	Member of Board of Directors
Kelly Kramer	Member of Board of Directors
Kevin Lofton	Member of Board of Directors
Daniel O'SDay	Chairman of Managing Board
Merdad Parsey	Member of Executive Committee
Taiyin Yang	Member of Executive Committee
Andrew Dickinson	Member of Executive Committee
Brett Pletcher	Member of Executive Committee
Christi L. Shaw	Member of Executive Committee
Flavius Martin	Member of Executive Committee
Johanna Mercier	Member of Executive Committee
Jyoti Mehra	Member of Executive Committee